3 Reasons Pfizer's Imminent Upjohn-Mylan Merger Is Great News for Investors
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more.
A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's Upjohn unit with Mylan to form a new entity, Viatris. Pfizer's spinoff of Upjohn will happen at the close of business on Nov. 13, 2020, with the merger of Upjohn and Mylan closing three days later.
How will current Pfizer shareholders be impacted? It's positive from nearly every angle. Here are three reasons why the imminent Upjohn-Mylan merger is great news for investors.
Source Fool.com
